Hernando-Requejo Ovidio, Olombrada Maria Victoria Torres, Bravo Irene Alda, Moreno Leire Arbea, López-Campos Fernando, Gonzalez Mercedes López, Martín Margarita Martín, Macías Virginia Morillo, De la Pinta Carolina
Radiation Oncology Department, Sanchinarro University Hospital, Madrid, Spain.
Radiation Oncology Department, University Hospital Fuenlabrada, Madrid, Spain.
Rep Pract Oncol Radiother. 2024 Jul 22;29(3):340-347. doi: 10.5603/rpor.101096. eCollection 2024.
The GI Tumors Workgroup, a division of the Spanish Society of Radiation Therapy, conducted a survey in December 2020 to assess the adherence of radiation oncologists in Spain to international guidelines for gastrointestinal tumors.
Using Google Forms, we designed a survey covering treatments for esophageal, gastric, pancreatic, and rectal cancers.
In esophageal cancer treatment, neoadjuvant chemoradiation was the standard in 76.7% of institutions. Radiation doses range from 41.1 to 50.4 Gy in conventional fractionation. Planning positron emission tomography-computed tomography (PET-CT) was performed in 83.3% of centers, and intensity-modulated radiation therapy/volumetric-arc radiation therapy (IMRT/VMAT) was the preferred technique in 86.7% of institutions. For gastric cancer, 71.4% followed perioperative chemotherapy guidelines. In the case of adjuvant radiotherapy, the majority prescribed 45-50.4 Gy, and 82.1% used IMRT/VMAT for treatment. For pancreas cancer, neoadjuvant chemotherapy followed by surgery in borderline resectable tumors and induction chemotherapy followed by radical radiotherapy for non-resectable tumors were the most frequent approaches. IMRT/VMAT was the primary technique. Locally advanced rectal cancer treatment is mainly based on neoadjuvant radiotherapy in all institutions. The preferred radiation doses typically range from 45 to 50 Gy in conventional fractionation. IMRT/VMAT was standard in most Institutions.
Spain's radiotherapy practices among respondents generally align with international guidelines for GI tumors highlighting Spain's commitment to evidence-based medical practice.
胃肠肿瘤工作组是西班牙放射治疗协会的一个部门，于2020年12月进行了一项调查，以评估西班牙放射肿瘤学家对胃肠道肿瘤国际指南的遵循情况。
我们使用谷歌表单设计了一项涵盖食管癌、胃癌、胰腺癌和直肠癌治疗的调查。
在食管癌治疗中，76.7%的机构采用新辅助放化疗作为标准治疗方法。常规分割放疗剂量范围为41.1至50.4 Gy。83.3%的中心进行了计划正电子发射断层扫描-计算机断层扫描（PET-CT），86.7%的机构首选调强放射治疗/容积弧形调强放疗（IMRT/VMAT）技术。对于胃癌，71.4%的机构遵循围手术期化疗指南。在辅助放疗方面，大多数机构规定的剂量为45-50.4 Gy，82.1%的机构使用IMRT/VMAT进行治疗。对于胰腺癌，对于边界可切除肿瘤，最常用的方法是新辅助化疗后手术；对于不可切除肿瘤，是诱导化疗后根治性放疗。IMRT/VMAT是主要技术。在所有机构中，局部晚期直肠癌的治疗主要基于新辅助放疗。常规分割放疗的首选剂量通常为45至50 Gy。大多数机构以IMRT/VMAT为标准治疗方法。
受访者中西班牙的放疗实践总体上符合胃肠道肿瘤的国际指南，这突出了西班牙对循证医疗实践的承诺。
